Relevant bibliographies by topics / Patient data. combined medium for autologous

Contents

  1. Journal articles
  2. Conference papers

Academic literature on the topic 'Patient data. combined medium for autologous'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Patient data. combined medium for autologous.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Patient data. combined medium for autologous"

1

Anders, Sven, Martin Volz, Hubert Frick, and Jörg Gellissen. "A Randomized, Controlled Trial Comparing Autologous Matrix-Induced Chondrogenesis (AMIC®) to Microfracture: Analysis of 1- and 2-Year Follow-Up Data of 2 Centers." Open Orthopaedics Journal 7, no. 1 (2013): 133–43. http://dx.doi.org/10.2174/1874325001307010133.

Full text
Abstract:
Microfracture (MFx) is currently the recommended option for the treatment of small cartilage defects but is not regarded as suitable for the treatment of defects larger than 2.5 cm2. To extent its applicability to medium-sized defects MFx has been combined with a collagen type I/III matrix (Chondro-Gide®). This technique is called Autologous Matrix-Induced Chondrogenesis (AMIC®) and meanwhile a clinically established treatment option for localized full-thickness small- to medium-sized cartilage defects. Despite its more spreading clinical use, clinical data published so far are limited to main
APA, Harvard, Vancouver, ISO, and other styles
2

Ganesan, Saravanan, Ezhilarasi Chendamarai, Jayandharan G. Rao, et al. "Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data." Blood 118, no. 21 (2011): 947. http://dx.doi.org/10.1182/blood.v118.21.947.947.

Full text
Abstract:
Abstract Abstract 947 About 5–10% newly diagnosed and about 20–30% of relapsed acute promyelocytic leukaemia (APL) patients will have disease recurrence after receiving currently accepted standards of care. There are a limited number of drugs in the armamentarium for treatment of APL. Preliminary work from our laboratory suggests that stromal cell adhesion mediated drug resistance (CAM-DR) is probably significant with arsenic trioxide (ATO) and is seen both in APL cell lines (n=8; figure 1A) and primary APL cells (n=26; data not shown). Preliminary data suggests that bortezomib (Bo) has cytoto
APA, Harvard, Vancouver, ISO, and other styles
3

Liu, Yu, Li Wang, Haocheng Yu, Samir S. Parekh, Eric Schadt, and Jun Zhu. "ISS stage and network risk score to predict benefits of multiple myeloma treatment options." Journal of Clinical Oncology 38, no. 15_suppl (2020): e20511-e20511. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e20511.

Full text
Abstract:
e20511 Background: Multiple myeloma (MM) is molecularly heterogeneous with many treatment regimens developed targeting different aspects of the disease. Multi-omics studies are now widely available, facilitating a precision medicine approach for personalized MM treatments. However, data from these studies vary with respect to treatment regimens, patient age, disease stage, and genomic alterations, thus complicating identification of treatment effects. Methods: From a Multiple Myeloma Molecular Causal Network (M3CN) model we previously described, we identified a prognostic subnetwork (prognNET)
APA, Harvard, Vancouver, ISO, and other styles
4

Golay, Josée, Anna D’amico, Gianmaria Borleri, et al. "Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients." Blood 122, no. 21 (2013): 3272. http://dx.doi.org/10.1182/blood.v122.21.3272.3272.

Full text
Abstract:
Abstract Background The combined use of chemotherapy and monoclonal antibodies has proved highly effective for the treatment of CLL but often results in severe life threatening immunosuppression. The development of adoptive therapy with autologous T cells could be clinically relevant to overcome these problems. Methods We have devised a novel, simple and efficient method for ex vivo expansion of normal autologous T cells from the peripheral blood of CLL patients for adoptive therapy, using blinatumomab (CD3xCD19) and rhIL-2 in serum-free medium. The complete phenotype of in vitro expanded T ce
APA, Harvard, Vancouver, ISO, and other styles
5

Aparicio-Soto, Marina, Caterina Curato, Franziska Riedel, Hermann-Josef Thierse, Andreas Luch, and Katherina Siewert. "In Vitro Monitoring of Human T Cell Responses to Skin Sensitizing Chemicals—A Systematic Review." Cells 11, no. 1 (2021): 83. http://dx.doi.org/10.3390/cells11010083.

Full text
Abstract:
Background: Chemical allergies are T cell-mediated diseases that often manifest in the skin as allergic contact dermatitis (ACD). To prevent ACD on a public health scale and avoid elicitation reactions at the individual patient level, predictive and diagnostic tests, respectively, are indispensable. Currently, there is no validated in vitro T cell assay available. The main bottlenecks concern the inefficient generation of T cell epitopes and the detection of rare antigen-specific T cells. Methods: Here, we systematically review original experimental research papers describing T cell activation
APA, Harvard, Vancouver, ISO, and other styles
6

Zhang, Jing, and Bao-An Chen. "Traditional Chinese Medicine Is Used to the Maintenance Therapy of Diffuse Large B Cell Lymphoma." Blood 134, Supplement_1 (2019): 5316. http://dx.doi.org/10.1182/blood-2019-126604.

Full text
Abstract:
Background: Diffuse large B cell lymphoma (DLBCL) is one of the most common malignancy hematologic disease in China. At present, the NCCN recommended first-line therapy to DLBCL is: rituximab combined with cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) or etoposide, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-EPOCH). For the medium-risk and high-risk adult patients, autologous hematopoietic stem cell transplantation (auto-HSCT) is recommended as consolidation therapy. However, no maintenance therapy is recommended. A number of clinical trials of rituximab or
APA, Harvard, Vancouver, ISO, and other styles
7

Quach, Hang, Daniel North, Susanna Freddi, Shuh Y. Tan, Lenny Straszkowski, and Harshal Nandurkar. "High GRP78 (78-kDa Glucose-Regulated Protein) Expression Predicts for a Favorable Clinical Outcome in Patients with Multiple Myeloma and May be a Potentially Useful Therapeutic Target in the Treatment of Multiple Myeloma." Blood 126, no. 23 (2015): 4206. http://dx.doi.org/10.1182/blood.v126.23.4206.4206.

Full text
Abstract:
Abstract Background: GRP78 (78-kDa glucose-regulated protein) is a molecular chaperone that is upregulated during cellular stress. It has been well demonstrated that GRP78 upregulation is associated with chemoresistance and metastasis in solid tumours. GRP78 has not been widely explored in multiple myeloma (MM), however, we and others have shown that GRP78 is much more overexpressed in myeloma cell lines compared to other cell lines. To assess the clinical relevance of GRP78 overexpression in MM, we investigated the association of plasma cell GRP78 expression on primary bone marrow (BM) trephi
APA, Harvard, Vancouver, ISO, and other styles
8

Xiao, Juan, Bing Han, Wanling Sun, Yuping Zhong, and Yongji Wu. "Ex Vivo Expansion and Long-Term Hematopoietic Reconstitution Ability of Sorted CD34+CD59+ Cells from Patients with Paroxysmal Nocturnal Hemoglobinuria." Blood 112, no. 11 (2008): 2324. http://dx.doi.org/10.1182/blood.v112.11.2324.2324.

Full text
Abstract:
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder characterized by intravascular hemolysis, venous thrombosis, and bone marrow (BM) failure. Until now, allogeneic hematopoietic stem cell transplantation is still the only way to cure PNH. Eculizumab, although very promising, is not the eradication of the disease because of raising the possibility of severe intravascular hemolysis if therapy is interrupted. Here we enriched the residual bone marrow normal progenitor cells (marked by CD34+CD59+) from PNH patients, tried to find an effective way of exp
APA, Harvard, Vancouver, ISO, and other styles
9

Naumann, A., N. Rotter, J. Bujía, and J. Aigner. "Tissue Engineering of Autologous Cartilage Transplants for Rhinology." American Journal of Rhinology 12, no. 1 (1998): 59–64. http://dx.doi.org/10.2500/105065898782102972.

Full text
Abstract:
In reconstructive surgery there is increasing demand for cartilage transplants to fill defects, especially nose and/or outer ear defects. Tissue engineering is one of the most modern pathways to generate autologous cartilage transplants. Isolated chondrocytes obtained from a tiny patient's biopsy were seeded on bioresorbable preshaped cell carriers to provide a 3-dimensional cell arrangement as in vivo. The combined use of these cell carriers in form of a non-woven mesh and a constant medium perfusion was performed to generate a cartilage-like cell-polymer-construct, which was finally subcutan
APA, Harvard, Vancouver, ISO, and other styles
10

Pilco Pilco, Rocio Matilde, Eduardo Rene Arias Salazar, Juan Sebastian Ordóñez Lasso, et al. "Functional and aesthetic outcomes of combined reconstructive tchniques in complex abdominal surgery." Ibero-American Journal of Health Science Research 4, no. 2 (2024): 64–71. http://dx.doi.org/10.56183/iberojhr.v4i2.643.

Full text
Abstract:
Background: Complex abdominal surgeries, necessitated by severe conditions like cancer, trauma, and inflammatory diseases, require advanced expertise and precise, multifaceted techniques to restore function and appearance. This review systematically assesses the outcomes of combined reconstructive techniques, such as mesh reinforcement, component separation, flap reconstruction, and laparoscopic-assisted repairs, in achieving optimal functional and aesthetic results. Methodology: RCTs, cohort studies, and case series on reconstructive techniques in complex abdominal surgeries for adults were i
APA, Harvard, Vancouver, ISO, and other styles
More sources

Conference papers on the topic "Patient data. combined medium for autologous"

1

Premasiri, A., G. Happawana, and A. Rosen. "Porous Media Tumor Model for Light Penetration and Oxygen Diffusion During Photodynamic Therapy." In ASME 2008 International Mechanical Engineering Congress and Exposition. ASMEDC, 2008. http://dx.doi.org/10.1115/imece2008-66480.

Full text
Abstract:
Photodynamic therapy (PDT) is an FDA approved, effective, and minimally invasive cancer treatment modality with few side effects. PDT requires three major components; photosensitizing agent, activation light, and molecular oxygen. Optimization of PDT for an individual patient requires good therapeutic selectivity and high efficacy, where the design of such an effective protocol is based on the understanding of the interaction of key therapeutic components with tumor tissue. Tumor models expressive of changes during the growth of tumor along with the behavior of PDT components facilitate the ab
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Patient data. combined medium for autologous' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography